Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
researchsquare; 2024.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-4240360.v1

ABSTRACT

Introduction: The COVID-19 pandemic and pre-eclampsia both present significant health challenges worldwide, with emerging evidence suggesting a genetic interlinkage that could illuminate new therapeutic avenues. This study aims to explore the genetic relationship between the severity of COVID-19 and pre-eclampsia, with a focus on Single Nucleotide Polymorphisms (SNPs) in the NTSR1 gene and mechanisms of calcium ion transport. Method: We employed a combination of genetic epidemiology and molecular biology techniques, including comprehensive bibliometric analysis and Mendelian Randomization, to assess the correlation between specific SNPs related to the NTSR1 gene and the severity of both COVID-19 and pre-eclampsia. Result: Our findings reveal a significant genetic correlation between the severity of COVID-19 and pre-eclampsia, underscored by SNPs associated with the NTSR1 gene and calcium ion transport. This correlation suggests a shared genetic foundation that could exacerbate both conditions, providing insights into potential molecular interactions involved. Conclusion: The identification of shared genetic pathways between COVID-19 and pre-eclampsia highlights the importance of genetic insights in developing targeted therapeutic interventions. These results open up new avenues for the mitigation of these conditions, emphasizing the role of genetic epidemiology in shaping future healthcare strategies.


Subject(s)
COVID-19 , Eclampsia
2.
Int J Biol Sci ; 19(8): 2613-2629, 2023.
Article in English | MEDLINE | ID: covidwho-2322821

ABSTRACT

Aerobic glycolysis has pleiotropic roles in the pathogenesis of hepatocellular carcinoma (HCC). Emerging studies revealed key promoters of aerobic glycolysis, however, little is known about its negative regulators in HCC. In this study, an integrative analysis identifies a repertoire of differentially expressed genes (DNASE1L3, SLC22A1, ACE2, CES3, CCL14, GYS2, ADH4, and CFHR3) that are inversely associated with the glycolytic phenotype in HCC. ACE2, a member of the rennin-angiotensin system, is revealed to be downregulated in HCC and predicts a poor prognosis. ACE2 overexpression significantly inhibits the glycolytic flux as evidenced by reduced glucose uptake, lactate release, extracellular acidification rate, and the expression of glycolytic genes. Opposite results are noticed in loss-of-function studies. Mechanistically, ACE2 metabolizes Ang II to Ang-(1-7), which activates Mas receptor and leads to the phosphorylation of Src homology 2-containing inositol phosphatase 2 (SHP-2). SHP2 activation further blocks reactive oxygen species (ROS)-HIF1α signaling. Addition of Ang-(1-7) or the antioxidant N-acetylcysteine compromises in vivo additive tumor growth and aerobic glycolysis induced by ACE2 knockdown. Moreover, growth advantages afforded by ACE2 knockdown are largely glycolysis-dependent. In clinical settings, a close link between ACE2 expression and HIF1α or the phosphorated level of SHP2 is found. Overexpression of ACE2 significantly retards tumor growth in patient-derived xenograft model. Collectively, our findings suggest that ACE2 is a negative glycolytic regulator, and targeting the ACE2/Ang-(1-7)/Mas receptor/ROS/HIF1α axis may be a promising therapeutic strategy for HCC treatment.


Subject(s)
Angiotensin-Converting Enzyme 2 , Carcinoma, Hepatocellular , Liver Neoplasms , Humans , Angiotensin-Converting Enzyme 2/metabolism , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Liver Neoplasms/metabolism , Reactive Oxygen Species , Animals
3.
Int J Nanomedicine ; 17: 3325-3341, 2022.
Article in English | MEDLINE | ID: covidwho-1968915

ABSTRACT

Purpose: Current vaccines for the SARS-CoV-2 virus mainly induce neutralizing antibodies but overlook the T cell responses. This study aims to generate an exosomal vaccine carrying T cell epitope peptides of SARS-CoV-2 for the induction of CD8+ T cell response. Methods: Thirty-one peptides presented by HLA-A0201 molecule were conjugated to the DMPE-PEG-NHS molecules, and mixed with DSPE-PEG to form the peptide-PEG-lipid micelles, then fused with exosomes to generate the exosomal vaccine, followed by purification using size-exclusion chromatography and validation by Western blotting, liquid nuclear magnetic resonance (NMR) test and transmission electron microscopy. Furthermore, the exosomal vaccine was mixed with Poly (I:C) adjuvant and subcutaneously administered for three times into the hybrid mice of HLA-A0201/DR1 transgenic mice with wild-type mice. Then, the epitope-specific T cell responses were detected by ex vivo ELISPOT assay and intracellular cytokine staining. Results: The exosomal vaccine was purified from the Peak 2 fraction of FPLC and injected into the hybrid mice for three times. The IFN-γ spot forming units and the frequencies of IFN-γ+/CD8+ T cells were 10-82-fold and 13-65-fold, respectively, higher in the exosomal vaccine group compared to the Poly (I:C) control group, without visible organ toxicity. In comparison with the peptides cocktail vaccine generated in our recent work, the exosomal vaccine induced significantly stronger T cell response. Conclusion: Exosomal vaccine loading T cell epitope peptides of SARS-CoV-2 virus was initially generated without pre-modification for both peptides and exosomes, and elicited robust CD8+ T cell response in HLA-A transgenic mice.


Subject(s)
COVID-19 , Vaccines , Animals , CD8-Positive T-Lymphocytes , COVID-19/prevention & control , COVID-19 Vaccines , Epitopes, T-Lymphocyte , Humans , Mice , Mice, Transgenic , Peptides , Poly I-C , SARS-CoV-2
4.
Front Physiol ; 12: 586589, 2021.
Article in English | MEDLINE | ID: covidwho-1121740

ABSTRACT

Since the outbreak of Coronavirus Disease 2019 (COVID-19) in Wuhan, China, in December of 2019, it has rapidly become a global pandemic. Although acute respiratory disorder is the main manifestation of COVID-19, acute kidney injury (AKI) is another important extrapulmonary complication, which has a critical impact on the prognosis and mortality of patients. Current understanding about the exact pathogenesis of AKI in COVID-19 is unclear. Several studies have suggested that intrarenal, pre-renal and post-renal factors mediated collaboratively by direct virus attack, overloaded immune responses, drugs, sepsis, coagulation dysfunction, and underlying diseases may all be involved in the pathogenesis of AKI. This article reviews the current understanding of the pathogenesis of AKI in COVID-19.

SELECTION OF CITATIONS
SEARCH DETAIL